Caldolor

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Caldolor

Property Description
Active Ingredient Ibuprofen
Form Injectable solution (Liquid dosage form)
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General Purpose Management of pain, Reduction of fever
Origin Synthetic drug, Propionic acid derivative

Caldolor: Identity and Pharmacological Classification

Caldolor is the trade name for the sterile, intravenous (IV) preparation of the single active ingredient, Ibuprofen, which functions as a prescription-only medication. The substance is chemically classified as a Propionic acid derivative, placing it within the larger group of non-selective Nonsteroidal Anti-Inflammatory Drugs (NSAID). This classification is clinically recognized for its analgesic and antipyretic efficacy. Its primary roles are as an analgesic and antipyretic agent, distinguishing it as a non-opioid pain and fever modulator. Within various clinical settings, this intravenous form of Ibuprofen is used to address pain intensity and manage discomfort.


Composition and Form of the Preparation

This specific preparation is supplied as an injectable solution, which is a liquid dosage form intended solely for parenteral administration via infusion. The formulation is that of a synthetic drug where the active Ibuprofen is prepared in an aqueous solution base. The formulation is used clinically to manage pain and reduce fever, providing an alternative to oral administration. This delivery method is chosen when rapid therapeutic concentration is required or when patients are unable to swallow oral medications, a factor often relevant for hospitalized adult patients and specific pediatric patients.


General Purpose of the IV Analgesic

The overarching purpose of Caldolor is to provide effective management of pain, reduction of fever, and control of treatment of inflammation in acute clinical settings. A typical, neutral use scenario involves managing moderate pain following a surgical procedure where oral intake is temporarily restricted. It is utilized primarily for those who require a hospital-grade analgesic for symptoms or as an adjunct therapy. The product’s design focuses on supporting the need for systemic comfort and temperature normalization when timely IV infusion is medically necessary.

Regulatory References

  1. NIH, Intravenous Ibuprofen Review

What side effects are possible with Caldolor?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of intravenous ibuprofen (Caldolor) as documented in official government regulatory labeling. The information is provided for educational purposes and is not a substitute for professional clinical advice.


Classification of Common Adverse Reactions

Adverse reactions classified as Common (occurring in ge 1% of patients) primarily involve several physiological systems, according to regulatory documents. These frequently observed effects include nausea, vomiting, and flatulence (Gastrointestinal Disorders); headache and dizziness (Nervous System Disorders); and infusion site pain and infusion site reaction (Administration Site Conditions). Other common documented effects include anemia, edema, and changes in renal markers like increased blood urea nitrogen (BUN) or creatinine.


Serious Documented Adverse Reactions

Regulatory labeling specifies serious, potentially fatal, risks associated with the Nonsteroidal Anti-Inflammatory Drug (NSAID) class. These include the risk of serious gastrointestinal bleeding, ulceration, and perforation, which may occur at any time during use. Furthermore, the medicine is associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which may occur early in treatment and increase with the duration of use.

Serious hypersensitivity reactions, including anaphylactic reactions and severe skin reactions such as Stevens-Johnson syndrome (SJS), are also documented.


Population-Specific Safety Considerations

The label notes that older adults are at a greater risk for serious gastrointestinal and renal adverse effects. Use is contraindicated after 29 weeks of gestation due to the risk of fetal ductus arteriosus closure. The product is also contraindicated for the treatment of pain in the setting of coronary artery bypass graft (CABG) surgery.

Overdose and Emergency Response

Overdose Manifestations and Severity

An overdose of Caldolor (intravenous Ibuprofen) is officially documented in regulatory information to affect the Central Nervous System (CNS) and the Gastrointestinal (GI) system, among others. Manifestations may progress from common signs to severe systemic toxicity.

Documented Signs and Symptoms:

  • CNS: Drowsiness, dizziness, confusion, severe headache, and the potential for seizures or coma.
  • GI: Nausea, vomiting, abdominal pain, diarrhea, and the risk of significant internal bleeding.
  • Other: Tinnitus, difficult breathing, and wheezing.

Severe Systemic Outcomes: Overdose may lead to serious complications including acute renal failure, metabolic acidosis, and low blood pressure (shock). These severe outcomes require advanced management in a clinical setting.

When to Seek Immediate Medical Help

The official prescribing information mandates that individuals seek immediate medical attention for any suspected overdose. Emergency help is also required for signs of a severe reaction, such as anaphylaxis. Treatment is universally defined as symptomatic and supportive, as no specific antidote is available. Management procedures include continuous monitoring of vital signs, ECG, and blood/urine tests and may involve specific interventions like activated charcoal or airway support.

Therapeutic Uses of Caldolor

What Caldolor Treats: Main Uses and Benefits

The primary role of Caldolor, an intravenous formulation of Ibuprofen, is to provide effective symptomatic support in acute care settings. It is generally indicated for two main therapeutic domains: the management of pain and the reduction of fever. This medication is commonly used across conditions presenting with acute episodes where symptoms related to physical discomfort or systemic imbalance require focused management. It helps address symptom clusters that may become intense or disruptive, such as those arising during postoperative care or other hospital admissions.

Non-Opioid Symptom Control and Antipyresis

Caldolor contributes to improved comfort during periods of heightened systemic burden, often by playing a role in managing non-opioid pain management strategies. The intravenous form is considered relevant for both adult and pediatric patients (six months and older) who are unable to take oral medications. This medicine assists with maintaining comfort by supporting the patient during difficult episodes of acute pain and fever.


Quick Fact: Relief for Acute Discomfort

Quick Fact: Relief for Acute Discomfort Caldolor is commonly used in clinical settings that involve acute or unstable symptom patterns, assisting with the overall symptom load when short-term symptomatic assistance is needed.

Eligibility and Restrictions for Use

Who Can and Cannot Use Caldolor?

Eligibility for Caldolor (intravenous Ibuprofen) is strictly defined by regulatory authorities based on age, physiological status, and underlying health conditions.

Contraindicated Populations (Must Not Use)

Caldolor is contraindicated (absolutely prohibited) for patients with a known history of hypersensitivity or allergic-type reactions (e.g., asthma, urticaria) to aspirin or other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). It is also prohibited for the treatment of pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Additionally, it must not be used by patients with severe heart failure (NYHA Class IV), active gastrointestinal bleeding, or severe renal or hepatic insufficiency.

Age and Physiological Restrictions

Caldolor is approved for use in adult patients and pediatric patients 3 months of age and older. Use is not established in children younger than 3 months of age. Geriatric patients require caution due to an increased risk of serious adverse events.

Pregnancy and Condition-Based Limitations

Caldolor is contraindicated starting at 30 weeks gestation (third trimester of pregnancy) due to fetal risk; use between 20 and 30 weeks is restricted. Patients with a prior history of peptic ulcer disease or GI bleeding, as well as those with hypertension or fluid retention, require caution and monitoring during use.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Caldolor

Interaction Scope

Property Description
Medicinal product categories with documented interactions NSAIDs, Anticoagulants, Antiplatelets, Antihypertensives (ACE/ARB/Beta-Blockers), Diuretics, SSRIs/SNRIs, Corticosteroids.
Specific interacting medicines (if explicitly listed) Aspirin, Lithium, Digoxin, Methotrexate, Warfarin, Furosemide, Thiazides.
Mechanistic basis of interactions (only if stated in label) Reduction of renal clearance, Interference with hemostasis, Diminishment of antihypertensive effect, Reduction of natriuretic effect.

Interaction Classifications (High-Level)

Classification Description
Interaction severity classification (as defined in official documents) Contraindicated (e.g., CABG setting, hypersensitivity), Significant (e.g., bleeding risk, altered serum levels), Use with Caution.
Interaction-context constraints (as defined in official documents) Formal prohibition tied to CABG surgery and Hypersensitivity to Aspirin/NSAIDs.

Resulting Interaction Structure

Official Interaction Statements

  • Co-administration is contraindicated in the peri-operative period of CABG surgery.
  • Concomitant use with Anticoagulants and Antiplatelet drugs significantly increases the risk of bleeding.
  • Co-administration with Lithium or Digoxin may increase serum levels of these medicines.
  • Co-administration with ACE Inhibitors or ARBs may diminish the antihypertensive effect and, in elderly or renally impaired patients, risk deterioration of renal function.
  • Alcohol consumption (three or more drinks daily) increases the risk of gastrointestinal bleeding.

Connection to the overall interaction profile

Regulatory documents define the product's interaction structure primarily through pharmacodynamic antagonism leading to diminished therapeutic effects of co-administered antihypertensives and diuretics, and through additive adverse effects that increase the risk of bleeding and gastrointestinal harm. The profile also addresses pharmacokinetic interactions resulting in elevated plasma concentrations of specific co-administered medicines, such as Lithium and Methotrexate, and includes formal restrictions based on procedural and hypersensitivity risk.

Mechanism of Action

How Caldolor Works

Caldolor exerts its effect by engaging mechanisms that modify enzymatic activity at the molecular level. This leads to biochemical changes that modulate signaling pathways across different physiological systems.


Targeting the Cyclooxygenase Enzyme System

This domain covers the drug's competitive and reversible inhibition of the Cyclooxygenase (COX-1 and COX-2) enzymes. This molecular interference blocks the conversion of arachidonic acid into prostanoids, which are local signaling molecules, thereby interrupting the early step of the prostanoid synthesis pathway.


Modulating Inflammatory and Thermoregulatory Pathways

The diminished synthesis of prostanoids results in reduced chemical input that sensitizes peripheral nerves and contributes to localized changes in vascular permeability. Furthermore, this mechanistic action influences the prostaglandin-mediated signal within the brain that elevates the body's internal thermoregulatory set point, resulting in heat dissipation.

Dosage and Administration Information

How to Use Caldolor (Ibuprofen) Injection

Caldolor is an intravenous (IV) formulation of ibuprofen administered exclusively by healthcare professionals in a clinical setting, following guidelines to ensure proper use.


Administration and Preparation

Caldolor must only be administered as a slow IV infusion.

Dosage Form Preparation Requirement Minimum Infusion Time
Concentrated Vial (800 mg/8 mL) Must be diluted to 4 mg/ mL or less using approved IV solutions. Adults: No less than 30 minutes. Pediatrics: No less than 10 minutes (for ages 6 months and older).
Ready-to-Use Bag (800 mg/200 mL) Requires no further dilution. Adults: No less than 30 minutes.

Official Dosing and Frequency

Caldolor dosing is based on the patient's age and, for younger children, weight. The lowest effective dose for the shortest duration is recommended.

  • Adult Dosing: Typically 400 mg or 800 mg per dose. May be repeated every 6 hours for pain management, or every 4 to 6 hours for fever, depending on the dose.
  • Pediatric Dosing (6 months to < 12 years): 10 mg/ kg per dose, up to a maximum of 400 mg per dose. Dosing is repeated every 4 to 6 hours as needed.
  • Maximum Daily Dose (Adults): Should not exceed 3,200 mg.

Special Procedural Condition

Patients must be well hydrated prior to receiving Caldolor administration to mitigate potential risks. The solution must also be visually inspected for particulate matter before use.

Recent Clinical Evidence

Research evidence / Overview of studies for Caldolor

Evidence for Use in Acute Pain Management

Research exploring intravenous Ibuprofen (Caldolor) was evaluated in studies focusing on acute pain management, including Randomized Controlled Trials (RCTs) and subsequent systematic reviews. Research was relevant in trials assessing short-term symptom patterns following surgical procedures. Researchers monitored patient-reported outcomes describing perceived discomfort (pain scores) and opioid consumption (to assess the concurrent use of other analgesics).

Studies report measurements of pain scores and recorded the amount of other pain medicine required. Findings describe patterns observed in the studies related to outcomes related to physical discomfort over defined time intervals (typically 24 to 48 hours). However, long-term effects are not fully established beyond the immediate hospital recovery period, and evidence quality varies across studies, meaning the data available reflect only the acute period.

Evidence for Use in Reducing Fever

Intravenous Ibuprofen (Caldolor) was evaluated in research focusing on the reduction of fever, which included Randomized Controlled Trials and data from integrated efficacy analyses. This research examined patients presenting with systemic or functional imbalance (elevated core body temperature). Outcomes related to physiological strain were monitored, including the change in body temperature and outcomes describing episodic or acute changes in temperature levels.

Research describes measurements of temperature change and how fever symptoms evolved in the observed populations, typically over the course of a few hours up to 24 hours. The key research limitation is that follow-up durations were limited, meaning the data available reflect only the immediate response in the acute care setting. Further research is needed to provide comparative evidence against certain alternative antipyretic options.

Research in Specific Patient Populations and Gaps

Studies included pediatric patients three months of age and older and older adults. Research provides context for how outcomes related to discomfort and systemic imbalance were measured in these groups. However, data for certain subgroups (such as older adults with complex conditions) remain insufficient, and research often focuses on short-term changes. The results are characteristic of the specific populations and conditions under which the research was conducted, and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Ibuprofen for Pain Control in Children (Review discussing efficacy and safety profile in pediatric populations)

Frequently Asked Questions (FAQ)

Common questions about Caldolor (FAQ)


Q: How quickly does Caldolor start working for post-operative pain?

Caldolor is given intravenously for the purpose of achieving rapid therapeutic concentrations. The official dosing schedule suggests a frequent dosing interval for pain (every 6 hours) and fever (every 4 to 6 hours), which generally indicates the anticipated duration of the therapeutic effect.


Q: How long do the effects of a Caldolor dose typically last?

The dosing schedule suggests the duration of effect; for pain management, doses are typically administered every 6 hours as needed. For fever reduction, a dose is given every 4 to 6 hours as needed, in accordance with the product's official information.


Q: What is the difference between Caldolor and oral ibuprofen?

Caldolor is the brand name for the intravenous (IV) injection of the active ingredient, ibuprofen. This IV form is used when patients cannot take oral medication or when rapid therapeutic concentration is required, distinguishing it from the oral pill form.


Q: Is it safe to use Caldolor if you have kidney problems?

The medicine is generally avoided in patients with advanced kidney disease, and its use requires careful monitoring in those with pre-existing renal impairment. Patients must also be adequately hydrated before administration to help reduce potential renal risks.


Q: Is it normal to feel slightly dizzy after receiving Caldolor?

Dizziness is listed in official regulatory documents as one of the frequently reported adverse reactions, meaning it was observed in at least 1% of patients in clinical trials.


Q: What kind of surgical pain is Caldolor most effective for?

Caldolor is indicated for the management of mild to moderate pain when used alone. For moderate to severe pain, it is indicated as an adjunct (or addition) to opioid analgesics in an acute care setting.


Q: Does Caldolor lower blood pressure?

Caldolor can cause the onset of new hypertension (high blood pressure) or worsening of existing hypertension. Official warnings also state that it can diminish the effectiveness of certain medications prescribed to lower blood pressure.


Q: Can Caldolor affect liver enzyme levels?

Official labeling notes that less common adverse reactions may include elevated hepatic enzymes (abnormal liver function test results). Furthermore, severe hepatic insufficiency (severe liver failure) is a contraindication.


Q: Is Caldolor safe during pregnancy (if used for short periods)?

Official regulatory information recommends avoiding NSAID use, including Caldolor, in pregnant women starting at 20 weeks of gestation due to the risk of fetal kidney problems. Use is contraindicated (prohibited) starting at 30 weeks of gestation.


Q: What are the signs of a serious, but rare, allergic reaction to Caldolor?

Serious hypersensitivity reactions are possible, although rare, and include severe reactions like anaphylaxis and severe skin reactions such as Stevens-Johnson syndrome (SJS). Signs of a serious reaction require immediate attention from a healthcare professional.


Q: Can Caldolor be used for chronic pain, or just acute pain?

The drug is indicated for the management of acute pain and fever. Official guidelines recommend using the drug for the shortest duration consistent with treatment goals, aligning it with short-term (acute) treatment rather than long-term (chronic) management.


Q: Can elderly patients safely receive Caldolor?

Caldolor can be used in older adults, but they are at a greater risk for serious adverse events, particularly those affecting the stomach, intestines, and kidneys, which requires careful clinical monitoring.


Q: Is Caldolor a strong painkiller?

Caldolor is indicated for the management of mild to moderate pain when used alone, and as an adjunct to opioid analgesics for moderate to severe pain, meaning it is used as part of a multi-drug approach for severe cases.


Q: What should I tell my doctor before getting Caldolor?

Official regulatory warnings indicate that a patient's medical history, including allergies to NSAIDs, heart conditions, kidney or liver disease, a history of GI bleeding or ulcers, and all current medications, must be disclosed to the healthcare provider.


Q: Can Caldolor cause stomach upset or digestive issues?

Nausea, vomiting, and flatulence are listed as common adverse reactions. Furthermore, like all NSAIDs, Caldolor carries warnings regarding the risk of serious gastrointestinal events, including bleeding, ulceration, and perforation.


Q: Is there research evidence showing Caldolor helps reduce opioid needs?

Caldolor is approved as an adjunct (additional) therapy to opioid analgesics for moderate to severe pain. Clinical trials measured a reduction in opioid consumption in patients receiving Caldolor compared to control groups.


Q: What is the typical timeframe for getting Caldolor in a hospital setting?

The medicine must be administered as a slow intravenous infusion after dilution. The infusion time must be no less than 30 minutes for adults, or no less than 10 minutes for pediatric patients.


Q: What does the research say about Caldolor's safety profile?

The safety profile is defined by official warnings regarding the risk of serious cardiovascular thrombotic events (such as heart attack or stroke) and serious gastrointestinal events (such as bleeding or ulcers). The drug carries a Boxed Warning about these risks.


Q: Can Caldolor be used to control high fever in adults?

Caldolor is indicated for the reduction of fever in adults and pediatric patients. Official regulatory data does not specify the treatment of only 'high' or 'low' fever, only the overall management of elevated body temperature.

How should Caldolor be stored and disposed of?

Caldolor (ibuprofen injection) is typically stored and handled in a clinical setting by healthcare professionals. Unopened vials or flexible bags should be maintained at a controlled room temperature, generally between 20 C and 25 C (68 F and 77 F), with permitted excursions to 15 C to 30 C (59 F to 86 F). The product must be protected from freezing.

After Caldolor concentrated vials are diluted for administration, the solution must be used within 24 hours. The diluted solution is stable at ambient temperature or when refrigerated between 2 C and 8 C (36 F and 46 F) during this period.

As a sterile, single-use product, any unused portion of the Caldolor solution must be discarded. Disposal of all unused or expired medication must adhere to federal and local guidelines for pharmaceutical waste, ensuring safe handling by trained personnel to protect public health and the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Caldolor found in:

A-Z Index: